High‐velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial
Academic Emergency Medicine · 2025-04 · 32 (4) · 403-413
DOI: 10.1111/acem.15038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Academic Emergency Medicine, online erschienen am 11.12.2024. Verfasst von David P Yamane und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Insufflation, Positive-Pressure Respiration, Noninvasive Ventilation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vapotherm Inc.
Themen: COPD
Abstract (Originalsprache)
Background
Acute exacerbations of chronic obstructive pulmonary disease (COPD) in the emergency department (ED) involve dyspnea, cough, and chest discomfort; frequent exacerbations are associated with increased mortality and reduced quality of life. Noninvasive positive pressure ventilation (NiPPV) is commonly used to help relieve symptoms but is limited due to patient intolerance. We aimed to determine whether high‐velocity nasal insufflation (HVNI) is noninferior to NiPPV in relieving dyspnea within 4 h in ED patients with acute hypercapnic respiratory failure.
Methods
This randomized control trial was conducted in seven EDs in the United States. Symptomatic patients with suspected COPD, partial pressure of carbon dioxide (pCO 2 ) ≥ 60 mm Hg, and venous pH 7.0–7.35 were randomized to receive HVNI ( n = 36) or NiPPV ( n = 32). The primary outcome was dyspnea severity 4 h after the initiation of study intervention, as measured by the Borg score. Secondary outcomes included vital signs, oxygen saturation, venous pCO 2 , venous pH, patient discomfort level, and need for endotracheal intubation.
Results
Sixty‐eight patients were randomized between November 5, 2020, and May 10, 2023 (mean age 65.6 years; 47% women). The initial pCO 2 was 77.7 ± 13.6 mm Hg versus 76.5 ± 13.6 mm Hg and the initial venous pH was 7.27 ± 0.063 versus 7.27 ± 0.043 in the HVNI and NiPPV groups, respectively. Dyspnea was similar in the HVNI and NiPPV groups at baseline (dyspnea scale score 5.4 ± 2.93 and 5.6 ± 2.41) and HVNI was noninferior to NiPPV at the following time points: 30 min (3.97 ± 2.82 and 4.54 ± 1.65, p = 0.006), 60 min (3.09 ± 2.70 and 4.07 ± 1.77, p < 0.001), and 4 h (3.17 ± 2.59 and 3.34 ± 2.04, p = 0.03). At 4 h, there was no difference between the groups in the pCO 2 mm Hg (68.76 and 67.29, p = 0.63). Patients reported better overall comfort levels in the HVNI group at 30 min, 60 min, and 4 h ( p = 0.003).
Conclusions
In participants with symptomatic COPD, HVNI was noninferior to NiPPV in relieving dyspnea 4 h after therapy initiation. HVNI may be a reasonable treatment option for some patients experiencing moderate acute exacerbations of COPD in the ED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Department of Anesthesia and Critical Care Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Department of Emergency Medicine, Cooper University Healthcare, Camden, New Jersey, USA.
- Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington, USA.
- Vapotherm, Inc., Exeter, New Hampshire, USA.
ORCID-Profile: Christopher W Jones, Andrew C Meltzer
Förderung
- Vapotherm Inc
Zitieren
APA
Yamane, D. P., Jones, C. W., Wilkerson, R. G., Oliver, J. J., Shahamatdar, S., Loganathan, A., Bolden, T., Heidish, R., Kelly, C. L., Bergeski, A., Whittle, J. S., Dungan, G. C., Maisiak, R., & Meltzer, A. C. (2025). High‐velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial. Academic Emergency Medicine, 32(4), 403-413. https://doi.org/10.1111/acem.15038
Vancouver
Yamane DP, Jones CW, Wilkerson RG, Oliver JJ, Shahamatdar S, Loganathan A, et al. High‐velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial. Academic Emergency Medicine. 2025;32(4):403-413. doi:10.1111/acem.15038
BibTeX
@article{Yamane2025,
author = {Yamane, David P and Jones, Christopher W and Wilkerson, R Gentry and Oliver, Joshua J and Shahamatdar, Soroush and Loganathan, Aditya and Bolden, Taylor and Heidish, Ryan and Kelly, Connor L and Bergeski, Amy and Whittle, Jessica S and Dungan, George C and Maisiak, Richard and Meltzer, Andrew C},
title = {High‐velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial},
journal = {Academic Emergency Medicine},
year = {2025},
volume = {32},
number = {4},
pages = {403--413},
doi = {10.1111/acem.15038}
}
EUVIMED